MethylScreen: DNA methylation density monitoring using quantitative PCR.

Area of Science:

• Molecular Biology
• Oncology
• Biotechnology

Background:

• Aberrant gene silencing via cytosine methylation is implicated in cancer development, including prostate cancer.
• Specific genes, such as GSTP1, show methylation patterns in prostate cancer, suggesting their potential as diagnostic markers.

Purpose of the Study:

• To develop and characterize a novel bisulfite-free DNA methylation detection assay, MethylScreen technology.
• To evaluate MethylScreen's performance in analyzing the GSTP1 gene's 5' region in various biological samples.

Main Methods:

• Development of MethylScreen technology, utilizing methylation-sensitive restriction enzymes (MSRE) and methylation-dependent restriction enzymes (MDRE).
• Application of MethylScreen to analyze GSTP1 methylation in cell lines, in vitro methylated DNA, and frozen tissue samples using quantitative PCR.
• Comparison of MethylScreen results with clone-based bisulfite genomic sequencing.

Main Results:

• MethylScreen technology can detect fully methylated DNA molecules at levels below 1% in mixed populations.
• The assay accurately quantifies the abundance of intermediately methylated DNA molecules.
• Quantitative PCR output from MethylScreen closely mirrored results obtained from bisulfite genomic sequencing.

Conclusions:

• MethylScreen provides a sensitive and quantitative bisulfite-free method for DNA methylation analysis.
• The technology shows promise for detecting and quantifying gene methylation relevant to cancer diagnosis, such as in prostate cancer.
• MethylScreen offers a viable alternative to traditional bisulfite-based methods for DNA methylation profiling.